Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
The disease can cause it to become harder and harder to breathe - and it's key you keep an eye out for symptoms ...
The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
Qureight Ltd and Avalyn Pharma Inc have announced a strategic partnership in progressive pulmonary fibrosis (PPF). The ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback